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The lengthy duration of multidrug therapy needed to cure tuberculosis (TB) poses
significant challenges for global control of the disease. Moreover, chronic inflammation
associated with TB leads to pulmonary damage that can remain even after successful
cure. Thus, there is a great need for the development of effective shorter drug regimens
to improve clinical outcome and strengthen TB control. Host-directed therapy (HDT)
is emerging as a novel adjunctive strategy to enhance the efficacy and shorten the
duration of TB treatment. Previously, we showed that the administration of CC-3052, a
phosphodiesterase-4 inhibitor (PDE4i), reduced the host inflammatory response during
Mycobacterium tuberculosis (Mtb) infection and improved the antimicrobial efficacy of
isoniazid (INH) in both the mouse and rabbit models. In the present study, we evaluated
the pharmacokinetics and explored the mechanism underlying the efficacy of a more
potent PDE4i, CC-11050, as adjunct to INH treatment in a mouse model of pulmonary
Mtb infection. Genome-wide lung transcriptome analysis confirmed the dampening of
inflammation and associated network genes that we previously reported with CC-3052.
Consistent with the reduction in inflammation, a significant improvement in Mtb control
and pathology was observed in the lungs of mice treated with CC-11050 plus INH,
compared to INH alone. This important confirmatory study will be used to help design
upcoming human clinical trials with CC-11050 as an HDT for TB treatment.
Keywords: Mycobacterium tuberculosis, immune modulation, phosphodiesterase-4 inhibitor, mouse model,
pulmonary tuberculosis, gene expression, host-directed therapy

INTRODUCTION
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is a leading killer among infectious
diseases, accounting for 1.5 million deaths and an estimated 9.6 million new cases in 2014.1
Standard short-course chemotherapy for pulmonary TB involves directly observed administration of four antibiotics, isoniazid (INH), rifampicin (RIF), ethambutol (EMB), and pyrazinamide
(PZA) for 2 months, followed by INH and RIF therapy for 4 months (1). The long duration
1
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of treatment presents difficulties for case management and
adherence, especially among patients from the poverty-stricken
communities that are most affected. Inadequate therapy or
treatment interruptions greatly elevate the risks of relapse and
acquisition of drug resistance, thereby increasing the potential
for further transmission and limiting therapeutic options for
the patient. Moreover, residual lung damage and an elevated
risk of reinfection can remain even after successful cure of TB
(2–4). To overcome these problems, there is a great need for the
development of effective shorter drug regimens to improve clinical outcome and enhance TB control. However, thus far, efforts
to shorten TB chemotherapy have proven unsuccessful (5). This
was most recently demonstrated in a series of randomized
controlled clinical trials, showing that substitution of INH or
EMB by one of the newer fluoroquinolones in a short-course
regimen administered for 4 months led to an increased incidence
of relapse, compared to the standard 6-month drug regimen (6).
Host-directed therapy (HDT) as an adjunct to conventional
antibiotic regimens is emerging as a novel strategy for shortening the duration of TB therapy (7, 8). An important advantage
of this approach is that Mtb cannot develop resistance to drugs
that target host cell functions. Evidence from both in vitro and
in vivo studies suggests that the extended duration of TB therapy
necessary to achieve cure may be explained by an ability of the
bacilli to shift to a slow or non-replicating state, in which they
are not responsive to standard doses of the currently available
antibiotics (5, 9). Non-replicating persistence of Mtb has been
associated with diverse environmental pressures exerted by the
host immune response, including hypoxia and the production of
reactive nitrogen intermediates, which are capable of driving the
bacilli toward a dormant phenotype in vitro (10).
Based on these reports, we hypothesized that dampening the
inflammatory response, which is associated with macrophage
activation and the environmental pressure on intracellular Mtb,
through the use of adjunctive HDT, could render the bacilli more
vulnerable to antibiotic-mediated killing. We have demonstrated
the value of this approach by showing, in both the mouse and
rabbit models, that adjunctive treatment with the small molecule
phosphodiesterase-4 inhibitor (PDE4i), CC-3052, reduced the
overt inflammatory response during Mtb infection and significantly improved INH-mediated bacillary clearance from the lungs
(11–13). While the PDE4i alone had no impact on the growth of
Mtb in vitro, within the lungs of CC-3052-treated animals, we
observed a significant reduction in the expression of several Mtb
stress response genes that are associated with dormancy (12). In
addition, we noted changes in the pathologic manifestations of
lung granulomas in both mice and rabbits in response to CC-3052.
The reduction in pathology induced by PDE4 inhibition in the
Mtb-infected lungs indicates that this treatment strategy may
help to limit pulmonary damage for improved clinical outcome
in TB patients.
The present study was undertaken to compare the impact of
CC-3052 in the murine TB model with a second PDE4i (CC11050), in preparation for a clinical trial of the latter drug in TB
patients. CC-11050 shows improved stability over CC-3052, has
demonstrated safety in humans, and has progressed to a phase II
clinical trial for treatment of lupus erythematosus and a phase I
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trial in HIV-infected adults on antiretroviral therapy. To better
understand the underlying molecular events associated with
PDE4 inhibition during TB chemotherapy, we recently studied
CC-11050 as an adjunct to INH treatment in the rabbit model
of pulmonary TB. We showed that CC-11050 reduced inflammation and pathology in the lungs and increased the antibiotic
responsiveness of the infecting Mtb (14). Here, we describe the
pharmacokinetics of CC-11050 in mice and show that the drug
reduces the inflammatory response and improves INH-mediated
bacillary clearance from the lungs. Taken together, the results of
our studies indicate that CC-11050 is a promising candidate for
HDT that may shorten the duration of treatment and improve
clinical outcome in patients with pulmonary TB.

MATERIALS AND METHODS
Bacterial Growth and Chemicals

Mycobacterium tuberculosis CDC1551 was grown in Middlebrook
7H9 media (BD Biosciences, MD, USA) as described in Ref. (11).
CC-11050 was provided by Celgene Corporation, Summit, NJ,
USA. All other chemicals were purchased from Sigma (Sigma–
Aldrich, MO, USA), unless stated otherwise.

Animal Welfare and Ethical Statement

Eight-week-old female B6D2F1 mice (The Jackson Laboratory,
Bar Harbor, ME, USA) were used in this study. All animal
procedures, including aerosol infection, oral gavage treatment,
postinfection/treatment monitoring, were performed following
standard protocols approved by the Institutional Animal Care
and Use Committee (IACUC) of Rutgers University and were
in compliance with institutional and governmental guidelines
regulating the care and use of laboratory animals in experimental
research.

Structure and In Vivo Pharmacokinetics
of CC-11050

The PDE4i, CC-11050 (N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)2-(methylsulfonyl) ethyl]-2,3-dihydro-3-oxo-1H-isoindol-4-yl](9Cl) cyclopropanecarboxamide) has an empirical formula of
C24H28N2O6S with one chiral center (Figure S1A in Supplementary
Material). Uninfected mice (n = 3 per group) were treated with 5,
25, or 50 mg/kg of CC-11050 by oral gavage. In another experiment, mice (n = 3) were treated with 50 mg/kg of CC-11050 plus
50 mg/kg of INH. A group of mice (n = 3) without treatment
were included as negative control. Venous blood was collected
at 1, 2, 5, 8, and 24 h after a single gavage administration of
CC-11050, with or without INH. Time-matched blood samples
were also collected from untreated mice. The animals were gavaged after overnight fasting and fed soon after gavage. Plasma
was collected by centrifugation of blood samples at 1,100× g for
10 min at 10°C and used for LC-MS/MS analysis.
The standard curve and quality control for CC-11050 were
prepared in mouse plasma diluted 1:1 with Sorenson’s Citrate
Buffer (25 mM; pH 1.5). Internal standard was prepared with
13
CD3-CC-11050 and mixed with the standard, quality control, or
test samples at 4:1:1 (13CD3-CC-11050:mouse plasma:Sorenson’s

2
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0.2 or 1 μg/ml of INH to test for the emergence of INH-resistant
Mtb; no CFUs were detected.

Citrate Buffer, vol/vol/vol) ratio. The mix was centrifuged at
4,000 rpm for 10 min at room temperature, and the supernatant was transferred to a 96-well assay plate. LC-MS/MS was
performed using a Sciex API 4000 triple quadrupole mass
spectrometer (Sciex, Division of MDS Inc., Canada) coupled to a
Shimadzu HPLC system (Shimadzu Scientific Instruments, MD,
USA). A Phenomenex Gemini column (5 μm, 2.0 mm × 50 mm;
Phenomenex, CA, USA) was used for chromatography with 0.1%
formic acid in water (mobile phase A) and 0.1% formic acid in
acetonitrile (mobile phase B). The parameters used were 0 min
for 10%B, 0.0–2.0 min for 10–75%B, 2.1–3.0 min for 95%B,
and 3.05–4.0 min for 10%B. For mass spectrometric detection,
a positive ion mode with turbo spray (ion source temperature
of 450°C) and a dwell time of 100 ms was used. Analytes were
quantified using multiple reactions monitoring (MRM) at the
following transitions: mass-to-charge ratio 473.1–178.1 and
477.1–182.1 m/z for CC-11050 and its internal standard, respectively. Peak area ratios of the analyte to its internal standard versus
analyte concentration, represented as quadratic regression plots,
were derived with 1/x2 weighting. Watson LIMS™ software was
used to determine the pharmacokinetic parameters (Thermo
Fisher, PA, USA). Peak plasma concentration (Cmax) and corresponding time (Tmax) were calculated from raw data. Area under
the plasma concentration-time curve (AUC) was determined by
linear/linear-log trapezoidal rule of non-compartmental model
using data from time 0 and the last measurable time point
(AUClast). All statistics were performed with Watson LIMS™
software. Plasma concentrations below the limit of quantitation
(BLOQ) were treated as 0 for calculation.

Histologic Analysis

Formalin-fixed lung tissues of Mtb-infected mice were paraffinembedded, cut into 5 μg sections, and stained with hematoxylin
and eosin (H&E) or acid fast staining by Ziehl–Neelsen (ZN)
method to visualize host cells and Mtb, respectively (IDEXXRADIL Laboratories Inc., MO, USA) as described in Ref. (11).
Stained sections were photographed in a Nikon Microphot-FX
photomicrographic system and analyzed with NIS-Elements
F3.0 software (Nikon Instruments Inc., NY, USA). Lung granuloma size was morphometrically measured using PathScan
Enabler IV scanner (Meyer Instruments, Houston, TX, USA)
and SigmaScan Pro software (Systat Software, Inc., CA, USA).
Histopathologic analysis and morphometry were performed by
an experienced pathologist blinded to the sample identity.

RNA Isolation and Microarray Analysis

Total RNA was isolated from the lungs of uninfected or Mtbinfected mice with or without CC-11050 treatment (n = 4 per
group) after 14 days of treatment using Trizol reagent (Invitrogen,
CA, USA) as described in Ref. (11). One microgram of total lung
RNA from each mouse was individually processed for cDNA
synthesis using SuperScript II system (Agilent Technologies,
CA, USA). The microarray experiment was performed using
mouse genome ST 1.0 microarray kit (Affymetrix, Santa Clara,
CA, USA), following a standard protocol2 for the data extraction
and analysis. RMA-normalized, log2-transformed array data
from individual mice from each group (n = 4 per group) were
compared as follows (i) Mtb-infected versus uninfected and (ii)
Mtb-infected CC-11050-treated versus untreated, using ANOVA
in Partek Genomics Suite (Partek Inc., St. Louis, MO, USA).
Significantly differentially expressed genes (SDEGs) were identified using 5% false discovery rate (FDR). The list of SDEGs was
further analyzed using QIAGEN’s Ingenuity® Pathway Analysis
(IPA®-QIAGEN, CA, USA) to determine significantly enriched
(P < 0.05) gene networks and canonical pathways as described
in Ref. (15). The microarray data has been submitted to GEO
(Accession number GSE83188).

Aerosol Infection of Mice and Estimation
of Bacterial Load

Female B6D2F1 mice were infected with Mtb CDC1551 using
an aerosol-exposure system (CH Technologies Inc., Westwood,
NJ, USA), as described in Ref. (11). The infection inoculum
was adjusted to implant 100–150 bacterial colony-forming
units (CFUs) in the lungs. To determine the actual number of
bacilli inoculated, Mtb-infected mice (n = 6) were euthanized
3 h postinfection (T = 0), and serial dilutions of whole lung
homogenates, prepared in sterile 1×PBS, were plated on
Middlebrook 7H11 agar (Difco Laboratories Inc., Detroit, MI,
USA); CFUs were counted following 4–6 weeks of incubation at
37°C in 5% CO2. Mtb-infected mice (n = 6) were euthanized at
14 days postinfection to determine the lung bacillary load (CFU)
and pathology at the time of initiating treatment. At 14 days
postinfection, Mtb-infected mice were allocated into four groups
(n = 24 per group) and treated with CC-11050 (50 mg/kg),
INH (50 mg/kg), or CC-11050 plus INH. The fourth group of
Mtb-infected mice was left untreated as control. All drugs were
dissolved in water and administered daily through oral gavage.
At 28, 56, 84, and 112 days postinfection, mice from each group
(n = 5–6 per group per time point) were euthanized, and portions
of the lungs were used to prepare homogenates for CFU assay,
stored in formalin for histologic analysis, or frozen immediately
for RNA isolation. Serial dilutions of lung homogenates from
these time points were plated on 7H10 agar supplemented with

Frontiers in Immunology | www.frontiersin.org

Quantitative Real-time PCR

Total lung RNA (200 ng) was reverse-transcribed using Sprint RT
kit (Clontech, CA, USA); 10 ng of cDNA were used for quantitative real-time PCR (qPCR), with Brilliant II SYBR master mix
(Agilent Technologies, CA, USA) and gene-specific primers in
a Stratagene Mx3005P instrument (Agilent Technologies, CA,
USA). ROX was included in each reaction as an internal control. The qPCR assay was performed using four mouse samples
in duplicate per group; the data were analyzed using MxPro
Software (Agilent Technologies, CA, USA). Transcript levels of
Gapdh were used as a reference against the test genes. Fold change
in gene expression was calculated using the formula 2−ΔΔCt, where
2

3
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ΔCt is the difference in threshold cycle (Ct) between the target
gene and Gapdh; and ΔΔCt is the ratio between untreated and
CC-11050-treated samples. Primers were designed based on
nucleotide sequences obtained from PrimerBank.3

untreated mice 14 days after initiation of treatment (i.e., 28 days
postinfection) (Figure 1). Compared to the uninfected controls,
Mtb infection induced the expression of all five genes tested in the
lungs. Among these, CC-11050 treatment significantly reduced
the expression level of Pde4D (P = 0.0037) and Pde4Bi3 (Pde4B
isoform 3; P = 0.015). No significant change in the expression
of Pde4A, Pde4Bv3 (Pde4B variant 3), and Pde4C was noted
(Figure 1). Taken together, these results suggest that Pde4D and
Pde4Bi3 are potential targets of CC-11050, although this observation needs to be confirmed at the protein level.

Statistical Analysis

Student’s t-test in GraphPad Prism (GraphPad Software, CA,
USA) was used to analyze group-wise comparisons of the CFUs,
qPCR, and morphometric data. P < 0.05 was considered statistically significant. ANOVA in Partek Genomic Suite version 6.6
was used for microarray gene expression analysis, and righttailed Fisher’s exact test in ingenuity pathway analysis was used
to determine the significance for pathway/network analysis as
described in Ref. (15).

Genome-Wide Lung Transcriptome
Analysis of Untreated and CC-11050Treated Mtb-Infected Mice

A microarray-based global gene expression profiling was used
to determine the effect of CC-11050 treatment on Mtb-infected
mouse lungs at 14 days of treatment. Principal component
analysis (PCA) of the normalized data shows distinct clustering
of the uninfected and Mtb-infected with or without CC-11050
treatment groups (Figure 2A). The PCA map also shows that the
median expression level (±2SD) data within individual groups
segregate closely and far from the other groups. This observation
shows a high level of reproducibility of variables (state of infection and treatment) within and between the data obtained from
different groups. With an FDR of 5% applied to the array data, we
found 5,850 SDEGs in the lungs of Mtb-infected mice, relative to
uninfected controls. In the Mtb-infected CC-11050-treated mice,
1,277 SDEGs were observed, relative to the infected untreated
animals. Of these, 861 SDEGs were shared between the treated
and untreated Mtb-infected groups (Figure 2B). Among the total
genes, the expression of 875 SDEGs (685 upregulated and 190
downregulated) in the untreated and 47 SDEGs (29 upregulated
and 18 downregulated) in the CC-11050-treated group were
affected by more than 1.5-folds. Taken together, the microarray
data suggest that Mtb infection significantly affects the expression
of thousands of host genes in the lungs. Of these, the expression of a subset of these (14.7%) was significantly affected in

RESULTS
Pharmacokinetics of CC-11050

A single oral administration of CC-11050 at each of three dose
levels (5, 25, 50 mg/kg) demonstrated rapid absorption of the
drug, with peak plasma concentrations reached by 1–2 h (Tmax)
(Figure S1B in Supplementary Material). The average composite
exposures of CC-11050, measured by area under the curve
(AUClast) in the plasma of mice given 5, 25, and 50 mg/kg doses,
were 1,080, 2,800, and 10,200 ng × h/ml, respectively. As compared to the response to a single oral dose of CC-11050 (50 mg/
kg) alone, CC-11050 (50 mg/kg) given in combination with INH
(50 mg/kg), resulted in a delayed Tmax from 2 to 5 h (Table 1).
In addition, a slight increase in the maximum plasma concentration of CC-11050 (Cmax) was noted in mice treated with CC-11050
plus INH, compared to CC-11050 alone (1,610 versus 1,410 ng/
ml). Moreover, the AUClast for mice treated with CC-11050 plus
INH was slightly higher than for those treated with CC-11050
alone (13,900 versus 10,200 ng × h/ml, respectively).

CC-11050 Treatment Reduces Pde4
Expression in Mtb-Infected Mouse Lungs

To test the impact of CC-11050 treatment on the expression
pattern of Pde4, qPCR was performed using total RNA from
the lungs of uninfected, Mtb-infected, and CC-11050-treated or
3

https://pga.mgh.harvard.edu/primerbank/

TABLE 1 | Plasma levels of CC-11050 with or without INH in mice after a
single oral dose.
Sampling time (h)

1
2
5
8
24
Tmax (h)
Cmax (ng/ml)
AUClast (ng × h/ml)

Concentration (ng/ml)a
CC-11050 only

CC-11050 + INH

1,331.6 ± 136.97
1,409.47 ± 140.85
948.85 ± 128.7
820.6 ± 265.98
1.27 ± 1.1
2.0
1,410
10,200

905.35 ± 594.23
1,309.39 ± 214.08
1,609.18 ± 167.2
1,271.73 ± 249.18
4.96 ± 1.85
5.0
1,610
13,900

FIGURE 1 | Expression of host PDE4 genes in Mtb-infected untreated
(hatched bars) or CC-11050-treated (solid bars) mouse lungs, relative
to the uninfected controls. Experiment was performed in duplicate with
four biological replicates (n = 4 per group). *P = 0.0037 for Pde4D and
P = 0.015 for Pde4Bi3 between untreated and CC-1150-treated groups.

Values shown are mean ± SD.

a

Frontiers in Immunology | www.frontiersin.org

4

June 2016 | Volume 7 | Article 238

Subbian et al.

Immunotherapy for Tuberculosis

CC-11050-treated mouse lungs, we analyzed respective sets of
SDEGs using IPA (Table 2). The gene ontology (GO) analysis
revealed that host cell processes associated with infectious disease
and inflammatory response were among the most significantly
affected biological functions in the Mtb-infected untreated
group. This is consistent with the progressive pathology seen in
the mouse lungs (see below). In the infected CC-11050-treated
animals, biological functions associated with infectious disease,
gene expression, and host cell assembly and organization were
among the most significantly affected. As shown in Table 2, the
biological functions affected in the untreated group were of a
higher level of significance (10−34–10−07), compared to a moderate
level of significance for the CC-11050-treated group (10−06–10−02).
Taken together, the GO analysis suggests distinct changes in the
biological functions affected in the mouse lungs by Mtb infection
with or without CC-11050 treatment.

Selected Immune Network/Pathway
Analysis of SDEGs

Based on the GO results, we extended our analysis to explore
the TNF-α interaction, lung inflammatory response, Il-17, and
interferon (Ifn) signaling networks/pathways. These networks/
pathways play key roles in the host immune/inflammatory
response to Mtb infection and are likely to be affected by the
anti-inflammatory activities of PDE4 inhibitors (16). The expression pattern of selected SDEGs in these networks/pathways was
validated by qPCR (Figure S2 in Supplementary Material).

TNF-α Interaction Network

Among the SDEGs in the Mtb-infected untreated mouse lungs,
479 were associated with the TNF-α interaction network. Of
these, 246 genes were upregulated, including 51 genes induced
by more than twofold, while 234 genes were downregulated
(Figure 3A; Table S1 in Supplementary Material). The expression
of TNF-α-mediated inflammatory molecules, including Cxcl9,
Saa2, Cxcl10, and Irg1 (Table S1 in Supplementary Material), was
upregulated by more than 10-fold in the Mtb-infected untreated
FIGURE 2 | Genome-wide lung transcriptome of Mtb-infected mice
with or without CC-11050 treatment. (A) Principal component analysis
(PCA) map showing segregation of uninfected, Mtb-infected untreated, or
CC-11050-treated samples (n = 4 per group). The eclipse/oval shape
represents 2 × SD from the mean data. (B) Venn diagram showing unique
and shared SDEGs between Mtb-infected untreated (red) and CC-11050treated (blue) mouse lungs after 14 days of treatment. A false discovery rate
(FDR) of 5% was applied to select the SDEGs. Microarray data were
generated with four biological replicates per each group. Numbers in
parenthesis are the total SDEGs.

TABLE 2 | Gene ontology analysis of significantly differentially expressed
genes.
Biological function

the CC-11050-treated infected mice. Selected SDEGs from the
microarray, including Cyp10, Ly6a, Trdn, Irg1, Cxcl10, Ifng,
and Tnfa, were confirmed by qPCR. As shown in Figure S2 in
Supplementary Material, the expression pattern of these genes
was consistent between microarray and qPCR.

Gene Ontology Analysis of SDEGs

To determine the biological functions affected by the differential host gene expression in the Mtb-infected untreated and
Frontiers in Immunology | www.frontiersin.org

5

P value

Mtb-infected untreated versus uninfected
Infectious disease
Immunological disease
Inflammatory response
Cellular function and maintenance
Cellular growth and proliferation
Cell death and survival
Cellular movement
Cellular development

8.36E−34–4.77E−08
4.51E−31–1.36E−07
7.45E−31–2.26E−08
8.82E−48–1.08E−07
8.54E−34–1.12E−07
1.03E−33–6.24E−08
5.24E−33–1.27E−07
2.52E−32–1.12E−07

CC-11050-treated versus untreated
Infectious disease
Gene expression
Cellular assembly and organization
Cell morphology
Cellular growth and proliferation
Cellular function and maintenance

8.53E−05–1.64E−02
1.47E−06–1.80E−02
2.65E−05–2.38E−02
6.44E−05–2.38E−02
8.73E−05–2.29E−02
1.02E−04–2.38E−02
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Supplementary Material). To avoid repetition, SDEGs analyzed
in the TNF-α interaction network were excluded from the list of
genes included in the lung inflammation network. A subset of
137 out of 5,780 SDEGs in the infected untreated mouse lungs
were associated with the inflammatory response. Of these, 95
genes were upregulated, including I11β, Il6, Mmp14, Ccr5, Nos2,
Mcp1, Stat1, and Cxcr3, while 42 genes were downregulated. In
comparison, nine genes were upregulated, and four were downregulated in the infected CC-11050-treated animals (Figure 3B;
Table S1 in Supplementary Material). Thus, consistent with the
expression pattern of the TNF-α network, many of the SDEGs in
the inflammatory response were upregulated by Mtb infection.
These results suggest that CC-11050 dampened the expression of
key inflammatory response molecules triggered by Mtb infection
in the treated mouse lungs.

Il-17 Interaction Network

Recently, Il-17 has been implicated as a crucial cytokine in
the host immune/inflammatory response to Mtb infection
(17). We probed the SDEGs from Mtb-infected untreated and
CC-11050-treated mouse lungs to examine the differential
expression of genes associated with Il17. Of the total SDEGs,
30 genes were found to be associated with the Il-17 interaction
network. Of these, Mtb infection resulted in upregulation of 20
genes, including Nos2, Ifnγ, Ccl13, Tnfα, and Ccl5, which were
induced by more than twofold, and downregulation of 9 genes
(Figures 4A,B). In the infected untreated animals, Il17D was
downregulated, while no significant change was noted in Il17A
and Il17F expression. In contrast, only four genes (HmgB1, Il17F,
Entpd1, and HspB8) were significantly differentially expressed in
the lungs of infected CC-11050-treated mice; all of which were
affected by less than twofold (Figure 4B). In summary, while
97% of genes in the Il-17 interaction network were significantly
affected by Mtb infection, the expression of 87% of these genes
was dampened by CC-11050, suggesting downregulation of this
network in the infected treated mouse lungs.

FIGURE 3 | Intensity plot of TNF-α (A) and lung inflammatory response
(B) network gene expression in Mtb-infected mouse lungs with or
without CC-11050 treatment. UT, untreated; CC, treated with CC-11050.
Only genes expressed in CC are shown in italicized gene symbols. Red color
shows upregulation and blue color shows downregulation of gene
expression. Scale bar ranges from +3 (red) to −3 (blue).

Canonical IFN Signaling Pathway

Interferon signaling is a hallmark of the onset of the adaptive immune response to Mtb infection in mouse lungs (16).
As expected, many genes in this pathway, including Ifnγ, Stat1,
Stat2, Irf1, Irf9, Ifi35, and Ifit3, were upregulated in the mouse
lungs by Mtb infection (Figures 5A,B). However, in the infected
CC-11050-treated animals, with the exception of Ifngr3 that was
downregulated, the expression of all other genes in this pathway
remained at levels similar to uninfected controls (Figure 5B;
Table S1 in Supplementary Material).

animals. Compared to this, 33 SDEGs were upregulated, and 8
SDEGs were downregulated in the lungs of CC-11050-treated
infected animals (Figure 3A; Table S1 in Supplementary
Material). In these animals, none of the SDEGs was altered by
more than a twofold change in expression. Thus, CC-11050 treatment significantly dampened the expression of many SDEGs in
the TNF-α network that were upregulated in response to Mtb
infection in the mouse lungs.

CC-11050 Plus INH Treatment
Reduces Bacillary Load in
Mtb-Infected Mouse Lungs

Lung Inflammation Network

TNF-α is one of the key proinflammatory molecules involved
in driving the host inflammatory response during progressive
TB (16). Therefore, we investigated the expression profile of
the lung inflammation network in the Mtb-infected untreated
and CC-11050-treated mouse lungs (Figure 3B; Table S1 in

Frontiers in Immunology | www.frontiersin.org

To determine the impact of CC-11050 on treatment of Mtbinfected mice with INH, we enumerated the lung bacillary load
in all treatment groups over the duration of infection (Figure 6).
The inoculum at time 0 (3 h postinfection) was about 2 log10 CFU.
At the onset of treatment (14 days postinfection), the bacillary
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FIGURE 4 | Gene interaction network and intensity plot of SDEGs associated with Il-17 in Mtb-infected mouse lungs with or without CC-11050
treatment. (A) Interaction of member genes involved in Il-17 expression/regulation. Solid lines represent direct connection, and broken lines indicate
indirect link. Red color indicates upregulation, and green color depicts downregulation. (B) Intensity plot of SDEGs associated with Il-17 network. UT,
untreated; CC, treated with CC-11050. Red color shows upregulation, and blue color denotes downregulation of gene expression. Scale bar ranges from
+3 (red) to −3 (blue).

load had reached 4.2 log10 CFU. In mice left untreated or treated
with CC-11050 alone, the bacillary load increased to about 5.5
log10 by 28 days and remained at persistently high levels until
112 days postinfection in both groups (Figure 6A). No significant difference in the number of lung CFUs was noted between
untreated and CC-11050-treated mice at any of the time points
tested, indicating that CC-11050 does not have anti-Mtb activity and does not cause generalized immune suppression in the
Frontiers in Immunology | www.frontiersin.org

animals. In the mice treated with INH or INH plus CC-11050,
we observed a gradual reduction in the lung CFUs from 28
until 84 days postinfection, after which the INH alone group
showed no significant decline to 112 days. In contrast, the CFUs
continued to decline in the CC-11050 plus INH treatment group,
reaching undetectable levels in the lungs of five out of six animals
(P = 0.02) by 112 days postinfection (Figures 6A,B). Moreover,
lung homogenates from infected mice treated with CC-11050
7
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FIGURE 5 | Interaction and expression pattern of SDEGs involved in canonical interferon signaling pathway in Mtb-infected mouse lungs with or
without CC-11050 treatment. (A) Pathway map showing interaction of member genes involved in Ifn signaling pathway. Red color indicates upregulation, and
green color indicates downregulation. (B) Intensity plot of SDEGs associated with Ifn signaling. UT, untreated; CC, treated with CC-11050. Red color shows
upregulation, and blue color shows downregulation of gene expression. Scale bar ranges from +3 (red) to −3 (blue).

FIGURE 6 | Bacillary load in Mtb-infected mouse lungs with or without CC-11050 and/or INH treatment. (A) Bacterial CFUs at various time points in
different treatment groups. Treatment was started at 14 days postinfection. *P = 0.07 between INH (triangle) and INH plus CC-11050-treated groups (diamond)
(n = 6 per group per time point). (B) Individual data points at 112 days. One animal out of six from each of INH or INH plus CC-11050-treated groups had unusual
CFU pattern that can be an outlier or due to technical error. Excluding these two samples from the analysis led to a significant difference in lung CFUs at 112 days
postinfection between the two treatment groups (P = 0.02; n = 5 per group).

treatment groups (Figure 7). In the Mtb-infected untreated mice,
the size (area) of granulomas at 28 days postinfection reached
about 0.08 ± 0.059 mm2. At this time, significant differences in
the lesion area were already noted between the untreated mice
and those treated with INH alone (P = 0.0302) or with INH plus
CC-11050 (P = 0.0259). By 112 days postinfection, a significant
reduction in granuloma size was noted in the lungs of mice treated
with INH, with or without adjunctive CC-11050, compared to
the untreated group (P = 0.008 and 0.0371, respectively, for

plus INH yielded no detectable CFUs when plated on media containing INH, indicating that PDE4 inhibition was not associated
with the emergence of resistant organisms.

CC-11050 Plus INH Treatment Reduces
Lung Pathology in Mtb-Infected Mice

A morphometric analysis was carried out to compare the extent
of pathology in the lungs of Mtb-infected mice in the different
Frontiers in Immunology | www.frontiersin.org
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FIGURE 7 | Morphometric measurements of lung granulomas in
Mtb-infected mice treated with CC-11050 (hatched bars), INH
(horizontal bars), both (solid bars), or none (gray bars). *P = 0.0302
between INH and no treatment; P = 0.0259 between INH plus CC-11050
and no treatment at 28 days postinfection. *P = 0.008 and 0.0371,
respectively, for INH and INH + CC-11050, compared to no treatment group
(n = 4–6 per group per time point).

INH and INH plus CC-11050). Infected mice treated with INH
plus CC-11050 had smaller lesions, compared to those treated
with INH alone, although the difference was not statistically
significant (Figure 7).
Histologic examination of the lungs also revealed differences
in pathology between the treatment groups. At 28 days postinfection (14 days of treatment), the lungs of untreated mice showed
diffuse granulomas (0.5–1 mm diameter), comprising aggregates
of evenly dispersed macrophages and lymphocytes with few
polymorphonuclear cells (Figures S3A,B in Supplementary
Material). At this time, treatment with CC-11050 alone had no
significant impact on the size and structure of the lesions, confirming that CC-11050 was not immune-suppressive (Figures
S3C,D in Supplementary Material). In mice treated with INH
alone (Figures S3E,F in Supplementary Material) or INH plus
CC-11050 (Figures S3G,H in Supplementary Material), the
lesions were somewhat smaller than those in the untreated or
CC-11050-treated groups with much smaller areas of aggregated
lymphoid cells. By 112 days postinfection, the relative extent of
disease among the Mtb-infected untreated groups was similar
to those observed at 28 days, although the granulomas showed
a more structured cellular organization (Figure 8). In the lungs
of untreated mice, the granulomas had condensed somewhat
from the earlier time point and were beginning to coalesce
(Figures 8A,B). These lesions contained small aggregates of
macrophages with some scattered lymphocytes, surrounded by
regions of more concentrated lymphoid cells. Treatment of the
infected mice with CC-11050 alone did not result in significant
differences in the immune cell composition of lung lesions from
those seen in the untreated animals (Figures 8C,D). In contrast,
the granulomas in the lungs of mice treated with INH alone
were smaller and comprised mainly of lymphocytes surrounding small patches of macrophages at the center (Figures 8E,F).
Treatment with CC-11050 plus INH resulted in fewer and more
condensed lung lesions, compared to the other groups. These

Frontiers in Immunology | www.frontiersin.org

FIGURE 8 | Histology of Mtb-infected mouse lungs at 112 days
postinfection. Representative image of H&E stained mouse lung sections at
10× (A,C,E,G) and 40× (B,D,F,H) magnifications. (A,B) untreated; (C,D)
CC-11050-treated; (E,F) INH-treated; and (G,H) INH plus CC-11050-treated.
(A,C,E,G) are photographed at 10×, and (B,D,F,H) are photographed at 40×
magnification. Note the presence of multiple, coalescent, and larger
granulomas in the untreated and CC-11050-treated mouse lungs (A–D); in
contrast, the INH-treated mouse had a smaller (E,F), while the INH plus
CC-11050-treated animals had the smallest lung lesion (G,H).

lesions were composed of densely packed lymphocytes with few
interspersed macrophages (Figures 8G,H).

DISCUSSION
Host-directed therapy shows promise as an adjunct to conventional antibiotic treatment for TB to shorten the duration of
chemotherapy and improve outcome (8, 18). The study described
here extends our previous work demonstrating that selective
immune modulation with a small molecule PDE4i, as an adjunct
to the anti-TB drug INH, can reduce pathology and enhance antimicrobial activity in the mouse model of pulmonary TB (11–13).
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In this study, we compared the impact of CC-11050 on TB
treatment with our previous findings for CC-3052. Our results
confirm and expand our previous observations and provide
some information on the lung-specific PDE4 isoforms targeted
by CC-11050. Previous reports have indicated that not all small
molecule PDE4i drugs have the same capacity to improve TB
chemotherapy (19–22). While rolipram and cilomilast treatment
of Mtb-infected mice showed no impact on antibiotic-mediated
bacillary clearance in the mouse pulmonary TB model (19),
co-treatment of mice with roflumilast plus INH resulted in
significantly reduced CFUs in the lungs, compared to INH alone
(20), similar to our findings with CC-3052 and CC-11050. The
variation in action of these molecules may reflect diversity in the
enzyme specificities of the inhibitors. The family of PDE4 enzymes
has 4 known subtypes (PDE4A–D) and at least 15 isotypes, which
are differentially expressed in various tissue and cell types and
differentially targeted by specific inhibitors (23). For example, the
adverse gastrointestinal side effects, which limit pharmacologic
use of rolipram, have been associated with specific splice-variant
isoforms of Pde4D (21), while roflumilast appears to exert its
anti-inflammatory effects mainly through PDE4B (22). In the
present study, treatment with CC-11050 alone led to reduced
transcript levels of Pde4D and Pde4Bi3 in the lungs, suggesting
that these isoforms may be specifically targeted. However, our
analysis did not distinguish between Pde4D splice-variants, and
the effect of CC-11050 on these targets remains to be confirmed
at the protein level.
The pharmacokinetic experiment revealed more rapid and
greater absorption of CC-11050 in the mice than we observed in
rabbits at the same dose of 50 mg/kg (Tmax and Cmax of 1,410 ng/ml
and 2 h versus 163 ng/ml and 4 h, respectively) (14). These
findings may reflect differences between rabbits and mice in
gastrointestinal absorption, metabolism, tissue distribution,
and/or excretion of the PDE4i. Coadministration of the PDE4i
with INH to the mice resulted in a delay of the CC-11050 Tmax
to 5 h, and a moderate increase in plasma Cmax and AUClast.
These observations are likely explained by the well-documented
inhibitory effects of INH on drug metabolism, mainly through
its inhibition of several cytochrome P isoforms in the liver (24).
In contrast, our previous study in rabbits showed no effects of
INH on the pharmacokinetics of CC-11050 (14). Moreover, the
PDE4i caused no significant changes in plasma levels of INH in
co-treated rabbits. This observation may be relevant to the potential emergence of resistant bacilli when patients are treated with
anti-TB drugs and adjunctive HDT. Of note, no INH-resistant
bacilli have been recovered from any co-treated rabbits or mice
in our investigations of PDE4i (11). Despite the differences in
pharmacokinetics between the two animal models, the effects
of CC-11050 on host gene expression and INH-mediated Mtb
clearance were similar, supporting the likelihood for similar
responses in humans. Taken together, the results of our studies in
both the rabbit and mouse models provide a rationale for phase
I clinical trials to establish appropriate dosing and determine
the potential for drug–drug interactions between CC-11050 and
antimicrobials in humans.
The GO analysis revealed that host cell processes associated
with infectious disease, inflammatory response, and cellular

Frontiers in Immunology | www.frontiersin.org

function were among the most significantly affected biological
functions in the untreated Mtb-infected mice. We observed a
similar transcriptome profile in the lungs of Mtb-infected rabbits, in addition to significant changes in genes involved with
lipid metabolism and small molecule transport (14). These
additional biological functions may reflect differences between
the physiological response of mice and rabbits to Mtb infection, particularly with regard to the formation of differentiated
granulomas, which are seen in rabbits but not in mice (25).
Mtb-infected mice develop lesions within the lungs, composed of
immune cell aggregates with minimal structure and no hypoxia,
which enlarge and coalesce over time. In contrast, rabbits show
a progressive granulomatous response to Mtb infection, with
highly structured hypoxic lesions surrounded by a fibrotic
capsule. These lesions eventually liquefy and form open cavities,
similar to the response seen in humans with pulmonary TB (25).
Despite these differences, both models showed reduced signs of
pathology in response to CC-11050 adjunctive treatment (14).
This was demonstrated in mice by the reduced size in lung lesions
of CC-11050 plus INH-treated animals. Additionally, MMP14
and several genes in the fibrosis network, which were upregulated
by infection, were downregulated to basal (uninfected) levels in
response to CC-11050 treatment alone. Thus, despite the lack of
visible fibrosis in the lungs of Mtb-infected mice, these animals
displayed a gene expression profile in response to PDE4 inhibition that was consistent with the pathologic changes seen in
Mtb-infected rabbits receiving the same treatment.
Although the rabbit model of pulmonary TB effectively mimics the pathology of human disease, the rabbit genome has only
been completed to 7× coverage, with roughly 80% of the genes
annotated on the basis of predictions with limited functional
validation (Broad Institute). For this reason, the mouse model
provided a useful validation for our transcriptomic studies, particularly with regard to the early immune response to Mtb infection, which has been well studied in this animal. Genome-wide
lung transcriptome analysis revealed dampened inflammatory
response-associated network genes in CC-11050-treated mice.
Specifically, several genes of the TNF-α, lung inflammation, Il-17,
and Ifn signaling pathways/networks were upregulated in mouse
lungs by Mtb infection; expression of most of these genes was
significantly reduced by CC-11050 treatment.
Treatment of mice with CC-11050 plus INH led to a significant
improvement in antibiotic-mediated bacillary clearance from the
lungs, compared to INH alone. Similar to our previous results for
CC-3052 in Mtb-infected mice, CC-11050 did not significantly
affect the kinetics of bacillary clearance at early time points,
whereas at later time points, when INH alone showed a plateau
in Mtb killing, the PDE4i co-treated animals continued to show
a decline in CFUs, reaching undetectable levels in 5/6 animals
by 112 days postinfection. This alteration of the biphasic kill
curve seen with INH alone is consistent with our hypothesis that
modulation of the host innate immune response can lead to a
reduction in the population of bacilli shifting into a physiologic
state in which they are refractory to antibiotic killing (26). The
association between host environmental pressure and antibiotic
tolerance of Mtb was demonstrated in a recent study by Liu et al.,
where activation of Mtb-infected macrophages in vitro rendered
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the bacilli tolerant to four first-line TB drugs, each of which was
able to kill Mtb in resting macrophages (27). Transcriptional
analysis of the intracellular bacilli revealed a common set of
genes that were differentially expressed upon exposure to each of
the four antibiotics. Moreover, the perturbations in the bacillary
transcriptome caused by anti-TB drugs were strikingly similar to
the profile of differentially expressed Mtb genes observed inside
activated, compared to resting, macrophages (27). Thus, observations from the Liu et al., study suggest that the environmental
pressure on Mtb within activated macrophages induces a stress
response that renders the organisms tolerant to anti-TB drugs.
The safety of small molecule PDE4i as anti-inflammatory agents
is an important consideration in the selection of these drugs for
use in humans. Both mice and rabbits treated with CC-11050 or
CC-3052 alone retained their ability to control Mtb growth as the
infection progressed, indicating that adaptive immunity was not
adversely affected. In contrast, uncontrolled bacillary replication
in the lungs was a characteristic of generalized immune suppression, induced in mice by treatment with anti-TNF antibody or in
rabbits treated with the soluble TNF receptor etanercept (11, 28).
Thus far, we have evaluated PDE4i in the context of treatment of mice with a single anti-TB drug, INH. Because of the
steep killing curve observed when infected mice are initially
exposed to antibiotic, it may be difficult to see the additive effect
of a second antibiotic. In contrast, the killing curve in rabbits,
where the organisms are within fully differentiated granulomas,
is much slower, providing an opportunity to evaluate the impact
of CC-11050 on a multidrug regimen (14, 29). Consequently, we
are evaluating the efficacy of CC-11050, provided as an adjunct,
in combination with two first-line anti-TB drugs, INH plus RIF,
in the rabbit model of pulmonary Mtb infection. Our preliminary results indicate that, after 8 weeks of treatment (starting at
4 weeks postinfection), the combination of RIF plus INH shows
enhanced bacillary killing compared to INH alone. Here, again,
co-treatment of rabbits with CC-11050, together with INH and
RIF, shows reduced CFUs in the lungs compared to INH and RIF
alone. This study is currently in progress, and the results will be
reported in a future publication.
In conclusion, the results of our present and published studies,
conducted in both the mouse and rabbit models of pulmonary
TB using two alternative inhibitors, provide proof-of-concept
that adjunctive PDE4i significantly improves antibiotic-mediated
bacterial killing and reduces lung pathology and is a promising
candidate drug for HDT to improve treatment of humans with
pulmonary TB.
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FIGURE S1 | Structure of CC-11050 (A) and plasma levels of CC-11050 at
various time points up to 24 h in uninfected mouse treated with various
concentrations (B).
FIGURE S2 | Validation of microarray data by qPCR. Randomly selected
mouse genes from microarray data at 28 days postinfection was evaluated by
qPCR. Values shown are expression levels in CC-11050-treated mouse lungs,
compared to the untreated. Level of Gapdh expression was used to normalize
the data. The experiment was repeated in duplicate with four samples per
group. *P < 0.05; **P < 0.001.
FIGURE S3 | Histology of mouse lung at 28 days postinfection.
Representative images of mouse lung sections at 28 days postinfection
(14 days posttreatment), stained with H & E, showing the architecture of
granulomas with diffuse accumulation of inflammatory/immune cells. (A,B)
untreated; (C,D) CC-11050-treated; (E,F) INH-treated; (G,H) INH plus
CC-11050-treated. (A,C,E,G) are photographed at 10×, and (B,D,F,H) are
photographed at 40× magnification. Note that the granulomas in INH or INH
plus CC-11050-treated mouse lungs are smaller than the untreated or those
treated with CC-11050 alone.
TABLE S1 | List of SDEGs associated with TNF-α, lung inflammation,
Il-17, and Ifn signaling networks/pathways.

REFERENCES

4. Ross J, Ehrlich RI, Hnizdo E, White N, Churchyard GJ. Excess lung function
decline in gold miners following pulmonary tuberculosis. Thorax (2010)
65(11):1010–5. doi:10.1136/thx.2009.129999
5. Connolly LE, Edelstein PH, Ramakrishnan L. Why is long-term therapy
required to cure tuberculosis? PLoS Med (2007) 4(3):e120. doi:10.1371/
journal.pmed.0040120
6. Ruan Q, Liu Q, Sun F, Shao L, Jin J, Yu S, et al. Moxifloxacin and
gatifloxacin for initial therapy of tuberculosis: a meta-analysis of rando
mized clinical trials. Emerg Microbes Infect (2016) 5(1):e12. doi:10.1038/
emi.2016.12
7. Wallis RS, Hafner R. Advancing host-directed therapy for tuberculosis. Nat
Rev Immunol (2015) 15(4):255–63. doi:10.1038/nri3813

1. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al.
WHO’s new end TB strategy. Lancet (2015) 385(9979):1799–801. doi:10.1016/
S0140-6736(15)60570-0
2. Pasipanodya JG, Miller TL, Vecino M, Munguia G, Garmon R, Bae S, et al.
Pulmonary impairment after tuberculosis. Chest (2007) 131(6):1817–24.
doi:10.1378/chest.06-2949
3. Verver S, Warren RM, Beyers N, Richardson M, van der Spuy GD,
Borgdorff MW, et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med (2005)
171(12):1430–5. doi:10.1164/rccm.200409-1200OC

Frontiers in Immunology | www.frontiersin.org

11

June 2016 | Volume 7 | Article 238

Subbian et al.

Immunotherapy for Tuberculosis

8. Zumla A, Azhar EI, Arabi Y, Alotaibi B, Rao M, McCloskey B, et al. Hostdirected therapies for improving poor treatment outcomes associated with
the middle east respiratory syndrome coronavirus infections. Int J Infect Dis
(2015) 40:71–4. doi:10.1016/j.ijid.2015.09.005
9. Aldridge BB, Keren I, Fortune SM. The spectrum of drug susceptibility in
Mycobacteria. Microbiol Spectr (2014) 2(5):MGM2-0031-2013. doi:10.1128/
microbiolspec.MGM2-0031-2013
10. Chao MC, Rubin EJ. Letting sleeping dos lie: does dormancy play a role in
tuberculosis? Annu Rev Microbiol (2010) 64:293–311. doi:10.1146/annurev.
micro.112408.134043
11. Koo MS, Manca C, Yang G, O’Brien P, Sung N, Tsenova L, et al.
Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice.
PLoS One (2011) 6(2):e17091. doi:10.1371/journal.pone.0017091
12. Subbian S, Tsenova L, O’Brien P, Yang G, Koo MS, Peixoto B, et al.
Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs. PLoS
Pathog (2011) 7(9):e1002262. doi:10.1371/journal.ppat.1002262
13. Subbian S, Tsenova L, O’Brien P, Yang G, Koo MS, Peixoto B, et al.
Phosphodiesterase-4 inhibition combined with isoniazid treatment of
rabbits with pulmonary tuberculosis reduces macrophage activation
and lung pathology. Am J Pathol (2011) 179(1):289–301. doi:10.1016/j.
ajpath.2011.03.039
14. Subbian S, Tsenova L, Holloway J, Peixoto B, O’Brien P, Dartois V, et al.
Adjunctive phosphodiesterase-4 inhibitor therapy improves antibiotic
response to pulmonary tuberculosis in a rabbit model. EBioMedicine (2016)
4:104–14. doi:10.1016/j.ebiom.2016.01.015
15. Koo MS, Subbian S, Kaplan G. Strain specific transcriptional response in
Mycobacterium tuberculosis infected macrophages. Cell Commun Signal
(2012) 10(1):2. doi:10.1186/1478-811X-10-2
16. Lyadova IV, Panteleev AV. Th1 and Th17 Cells in tuberculosis: protection,
pathology, and biomarkers. Mediators Inflamm (2015) 2015:854507.
doi:10.1155/2015/854507
17. Khader SA, Gopal R. IL-17 in protective immunity to intracellular pathogens.
Virulence (2010) 1(5):423–7. doi:10.4161/viru.1.5.12862.Review
18. Churchyard GJ, Kaplan G, Fallows D, Wallis RS, Onyebujoh P, Rook GA.
Advances in immunotherapy for tuberculosis treatment. Clin Chest Med
(2009) 30(4):769–82, ix. doi:10.1016/j.ccm.2009.08.009
19. Maiga M, Ammerman NC, Maiga MC, Tounkara A, Siddiqui S, Polis M, et al.
Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment. J Infect Dis
(2013) 208(3):512–9. doi:10.1093/infdis/jit187
20. Maiga MC, Ahidjo BA, Maiga M, Bishai WR. Roflumilast, a type 4 phosphodiesterase inhibitor, shows promising adjunctive, host-directed therapeutic
activity in a mouse model of tuberculosis. Antimicrob Agents Chemother
(2015) 59(12):7888–90. doi:10.1128/AAC.02145-15

Frontiers in Immunology | www.frontiersin.org

21. Miró X, Pérez-Torres S, Puigdomènech P, Palacios JM, Mengod G. Differential
distribution of PDE4D splice variant mRNAs in rat brain suggests association with specific pathways and presynaptical localization. Synapse (2002)
45(4):259–69. doi:10.1002/syn.10100
22. Konrad FM, Bury A, Schick MA, Ngamsri KC, Reutershan J. The unrecognized
effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation.
PLoS One (2015) 10(4):e0121725. doi:10.1371/journal.pone.0121725
23. Houslay MD, Adams DR. PDE4 cAMP phosphodiesterases: modular enzymes
that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J (2003) 370(Pt 1):1–18.
24. Wen X, Wang JS, Neuvonen PJ, Backman JT. Isoniazid is a mechanism-based
inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human
liver microsomes. Eur J Clin Pharmacol (2002) 57(11):799–804. doi:10.1007/
s00228-001-0396-3
25. Flynn J, Tsenova L, Izzo A, Kaplan G. Experimental animal models
of tuberculosis. In: Kaufmann SHE, Britton WJ, editors. Handbook of
Tuberculosis – Immunology and Cell Biology. Weinheim: Wiley-VCH Verlag
GmBH & Co. KGaA (2008). p. 389–426.
26. McCune RM, Feldmann FM, Lambert HP, McDermott W. Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse
tissues. J Exp Med (1966) 123(3):445–68. doi:10.1084/jem.123.3.445
27. Liu Y, Tan S, Huang L, Abramovitch RB, Rohde KH, Zimmerman MD, et al.
Immune activation of the host cell induces drug tolerance in Mycobacterium
tuberculosis both in vitro and in vivo. J Exp Med (2016) 213(5):809–25.
doi:10.1084/jem.20151248
28. Tsenova L, O’Brien P, Holloway J, Peixoto B, Soteropoulos P, Fallows D, et al.
Etanercept exacerbates inflammation and pathology in a rabbit model of
active pulmonary tuberculosis. J Interferon Cytokine Res (2014) 34(9):716–26.
doi:10.1089/jir.2013.0123
29. Datta M, Via LE, Kamoun WS, Liu C, Chen W, Seano G, et al. Anti-vascular
endothelial growth factor treatment normalizes tuberculosis granuloma
vasculature and improves small molecule delivery. Proc Natl Acad Sci U S A
(2015) 112(6):1827–32. doi:10.1073/pnas.1424563112
Conflict of Interest Statement: VK and JZ are employees of Celgene Corporation.
GK is a member of the board of Celgene Corporation. All other authors: none
to declare.
Copyright © 2016 Subbian, Koo, Tsenova, Khetani, Zeldis, Fallows and Kaplan.
This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) or licensor are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.

12

June 2016 | Volume 7 | Article 238

